Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Grading ovarian serous carcinoma using a two-tier system.

Anais Malpica1, Michael T Deavers, Karen Lu

  • 1Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. amalpica@mdanderson.org

The American Journal of Surgical Pathology
|April 17, 2004
PubMed
Summary

A new two-tier grading system for ovarian serous carcinoma, focusing on nuclear atypia, shows promise for improved reproducibility. This system, along with residual tumor, is a significant independent prognostic factor in patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.

Nature communications·2026
Same author

High-grade Invasive Papillary Urothelial Carcinoma Arising in a Mature Cystic Teratoma of the Ovary: A Case Report, Including Its Molecular Profile, and a Literature Review.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026
Same author

Mixed tumor of the vagina with atypical features: a case report including clinical management.

Gynecologic oncology reports·2026
Same author

Extrauterine mesonephric-like carcinoma: a tumor with a cold lymphocytic immune microenvironment.

Virchows Archiv : an international journal of pathology·2026
Same author

Serous Ovarian Cancer Following Opportunistic Bilateral Salpingectomy.

JAMA network open·2026
Same author

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Area of Science:

  • Gynecologic Pathology
  • Cancer Grading Systems
  • Ovarian Cancer Research

Background:

  • Ovarian serous carcinoma grading is crucial for prognosis and treatment decisions.
  • Existing grading systems like Shimizu/Silverberg and FIGO have limitations in reproducibility.
  • A simplified, two-tier system based on nuclear atypia and mitotic rate is proposed.

Purpose of the Study:

  • To evaluate a novel two-tier grading system for ovarian serous carcinoma.
  • To assess the correlation of this system with established grading methods (Shimizu/Silverberg, FIGO).
  • To determine the prognostic significance of the new grading system in ovarian serous carcinoma.

Main Methods:

  • Retrospective analysis of 100 ovarian serous carcinoma cases (50 low-grade, 50 high-grade) over 28 years.

Related Experiment Videos

  • Evaluation of nuclear atypia and mitotic rate (per 10 high power fields) for the two-tier system.
  • Comparison with Shimizu/Silverberg and FIGO grading systems.
  • Multivariate analysis to identify independent prognostic factors.

    • Main Results:

    • The two-tier system demonstrated good correlation with Shimizu/Silverberg and FIGO grading.
    • Tumor grade by the new system and residual tumor were significant independent prognostic factors (P=0.04 and P=0.003, respectively).
    • Low-grade tumors showed a higher association with serous neoplasms of low malignant potential (60%) compared to high-grade tumors (2%).

    Conclusions:

    • The proposed two-tier grading system for ovarian serous carcinoma offers a simpler, potentially more reproducible approach.
    • This system, alongside residual tumor status, is a valuable prognostic indicator.
    • Further studies are needed to validate the system's widespread applicability and impact on patient management.